Cargando…
Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults
INTRODUCTION: The risk of poor vaccine immunogenicity and more severe influenza disease in HIV necessitate strategies to improve vaccine efficacy. METHODS: A randomized, multi-centered, controlled, vaccine trial with three parallel groups was conducted at 12 CIHR Canadian HIV Trials Network sites. T...
Autores principales: | Cooper, Curtis, Thorne, Anona, Klein, Marina, Conway, Brian, Boivin, Guy, Haase, David, Shafran, Stephen, Zubyk, Wendy, Singer, Joel, Halperin, Scott, Walmsley, Sharon |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064575/ https://www.ncbi.nlm.nih.gov/pubmed/21512577 http://dx.doi.org/10.1371/journal.pone.0017758 |
Ejemplares similares
-
Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023) -
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022) -
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022) -
Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren
por: Kamoltham, Thavatchai, et al.
Publicado: (2011) -
Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care
por: Bijani, Behzad, et al.
Publicado: (2019)